CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE) SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Disponible desde:

MYLAN PHARMACEUTICALS ULC

Código ATC:

M03AC11

Designación común internacional (DCI):

CISATRACURIUM

Dosis:

2MG

formulario farmacéutico:

SOLUTION

Composición:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

5ML

tipo de receta:

Prescription

Área terapéutica:

NEUROMUSCULAR BLOCKING AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0133260001; AHFS:

Estado de Autorización:

CANCELLED PRE MARKET

Fecha de autorización:

2018-06-15

Ficha técnica

_ _
_Page 1 of 30 _
_ _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION (PRESERVATIVE-FREE)
SOLUTION FOR INJECTION
2 MG/ML CISATRACURIUM (AS CISATRACURIUM BESYLATE)
5 ML SINGLE DOSE VIAL
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR
WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Preparation: August 18, 2014
Control No.: 176645
_ _
_Page 2 of 30 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
............................................................................................................
8
DRUG INTERACTIONS
............................................................................................................
9
DOSAGE AND ADMINISTRATION
......................................................................................
10
OVERDOSAGE
.........................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
16
STORAGE AND STABILITY
..................................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................